Table 2.

Frequency of adverse events during treatment period (weeks 0–12)

Adverse EventMonthly 
(n=33)Weekly
(n=36)Placebo
(n=36)P Valuea
Any adverse event26 (78.8)33 (91.7)28 (77.8)0.22
Elevated phosphorous13 (39.4)13 (36.1)15 (41.7)0.89
Elevated calcium1 (3.0)2 (5.6)1 (2.8)0.80
Elevated PTH2 (6.1)6 (16.7)4 (11.1)0.38
Elevated potassium0 (0.0)0 (0.0)3 (8.3)0.05
Elevated white blood count0 (0.0)0 (0.0)1 (2.8)0.38
Low albumin0 (0.0)0 (0.0)1 (2.8)0.38
Hospitalization11 (33.3)14 (38.9)13 (36.1)0.89
Infection11 (33.3)11 (30.6)8 (22.2)0.56
Cardiovascular2 (6.1)6 (16.7)3 (8.3)0.31
Respiratory2 (6.1)3 (8.3)3 (8.3)0.92
Constipation0 (0.0)2 (5.6)1 (2.8)0.38
Fluid overload0 (0.0)1 (2.8)2 (5.6)0.38
Nausea/vomiting/diarrhea4 (12.1)2 (5.6)3 (8.3)0.62
Hypotension3 (9.1)0 (0.0)2 (5.6)0.20
Hypertension0 (0.0)1 (2.8)0 (0.0)0.38
Fall3 (9.1)3 (8.3)1 (2.8)0.51
Other2 (6.1)4 (11.1)2 (5.6)0.62
  • Unless otherwise noted, values are expressed as n (%).

  • a Significant at P<0.05.